Monsanto Roundup Lawsuit

Thursday, May 29, 2008

GlaxoSmithKline in the News... and it ain't good news!

GSK submits non-statistically significant NDA for Promacta

Source: Pharmababble

Pharmababble's author writes:

An FDA reviewer said that Promacta, an experimental platelet-boosting drug seeking an indication for acute treatment of chronic idiopathic thrombocytopenia purpura from GSK, did not help control bleeding any better than a placebo. The reviewer wrote:

“The data provided in this NDA (new drug application) do not demonstrate statistically significant, robust … treatment effect in decreasing bleeding events,”

The FDA is already being stingy about approving NDAs when they demonstrate statistically significant effects. I can’t imagine the advisory board, which meets Friday, is going to issue a positive opinion about recommending an acute therapy for a chronic disease state, especially with non-statistically significant results.

I’m not a regulatory guy, so anyone want to explain the GSK reasoning to me?

----




Read the new book, The Evidence, However, Is Clear...The Seroxat Scandal

By Bob Fiddaman

ISBN: 978-1-84991-120-7
CHIPMUNKA PUBLISHING

AVAILABLE FOR DOWNLOAD HERE


PAPERBACK COMING SOON
Post a Comment